ReShape Lifesciences Secures $6M Investment to Revolutionize Weight-Loss Solutions

ReShape Lifesciences Inc., America’s premier weight-loss and metabolic health-solutions company, is proud to announce a successful funding round that raised $6,000,000.

This new investment is set to fuel the company’s continued efforts in advancing innovative, minimally invasive treatment options for obesity.

With a comprehensive approach that integrates medical devices, surgical alternatives, and virtual health support, ReShape Lifesciences is uniquely positioned to help millions of Americans achieve sustainable weight loss and overall wellness.

The recently completed funding round underscores investor confidence in ReShape Lifesciences’ proven track record in delivering effective weight-loss solutions.

The FDA-approved Lap-Band® program remains a flagship treatment that offers an effective and less invasive alternative to conventional surgical stapling procedures like gastric bypass or sleeve gastrectomy.

Additionally, the company’s investigational ReShape Vest™ System — currently being evaluated outside the U.S.

— presents a groundbreaking approach by mimicking the effects of gastric volume reduction without permanently altering patient anatomy.

This innovation represents the next generation of weight-loss solutions aimed at enabling rapid and safe weight loss for obese and morbidly obese individuals.

Moreover, the recent launch of the re-shapecare™ virtual health coaching program further complements the ReShape Lifesciences portfolio.

This reimbursed tele-health weight-management program is designed to support patients through lifestyle modifications necessary to maintain long-term weight loss.

With these integrated initiatives, ReShape Lifesciences Inc. is not only revolutionizing obesity treatment but also empowering patients to build a healthy life, one choice at a time.

The new funding will propel further research, development, and market expansion to broaden access to these transformative treatments and services.